Abstract
Heart failure with preserved ejection fraction (HFpEF) accounts for over half of prevalent heart failure (HF) worldwide, and prognosis after hospitalization for HFpEF remains poor. Due, at least in part, to the heterogeneous nature of HFpEF, drug development has proved immensely challenging. Currently, there are no universally accepted therapies that alter the clinical course of HFpEF. Despite these challenges, important mechanistic understandings of the disease have revealed that the pathophysiology of HFpEF is distinct from that of HF with reduced ejection fraction and have also highlighted potential new therapeutic targets for HFpEF. Of note, HFpEF is a systemic syndrome affecting multiple organ systems. Depending on the organ systems involved, certain novel therapies offer promise in reducing the morbidity of the HFpEF syndrome. In this review, we aim to discuss novel pharmacotherapies for HFpEF based on its unique pathophysiology and identify key research strategies to further elucidate mechanistic pathways to develop novel therapeutics in the future.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 41-63 |
| Number of pages | 23 |
| Journal | Annual Review of Pharmacology and Toxicology |
| Volume | 59 |
| DOIs | |
| State | Published - Jan 6 2019 |
Funding
S.S. has received research grants from Actelion, AstraZeneca, Corvia, and Novartis and consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Cardiora, Eisai, Ironwood, Merck, Novartis, Sanofi, and United Therapeutics. He is supported by the National Institutes of Health (R01 HL107577, R01 HL127028, and R01 HL140731) and American Heart Association (16SFRN28780016 and 15CVGPSD27260148). R.P. is supported by the National Heart, Lung and Blood Institute T32 postdoctoral training grant (T32HL069771).
Keywords
- Heart failure with preserved ejection fraction
- Pathophysiology
- Pharmacotherapy
ASJC Scopus subject areas
- Toxicology
- Pharmacology